FAPI-74 PET/CT Using Either 18 F-AlF or Cold-Kit 68 Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients.

Autor: Giesel FL; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany., Adeberg S; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center, Heidelberg, Germany.; Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany., Syed M; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.; Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany., Lindner T; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany., Jiménez-Franco LD; ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH, Dresden, Germany., Mavriopoulou E; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany., Staudinger F; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany., Tonndorf-Martini E; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.; Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany., Regnery S; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.; Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany., Rieken S; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany.; Department of Radiation Oncology, University Hospital Göttingen, Göttingen, Germany; and., El Shafie R; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany., Röhrich M; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany., Flechsig P; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany., Kluge A; ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH, Dresden, Germany., Altmann A; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany., Debus J; Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center, Heidelberg, Germany.; Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany., Haberkorn U; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany uwe.haberkorn@med.uni-heidelberg.de.; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany., Kratochwil C; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Jazyk: angličtina
Zdroj: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2021 Feb; Vol. 62 (2), pp. 201-207. Date of Electronic Publication: 2020 Jun 26.
DOI: 10.2967/jnumed.120.245084
Abstrakt: 68 Ga-fibroblast activation protein inhibitors (FAPIs) 2, 4, and 46 have already been proposed as promising PET tracers. However, the short half-life of 68 Ga (68 min) creates problems with manufacture and delivery. 18 F (half-life, 110 min) labeling would result in a more practical large-scale production, and a cold-kit formulation would improve the spontaneous availability. The NOTA chelator ligand FAPI-74 can be labeled with both 18 F-AlF and 68 Ga. Here, we describe the in vivo evaluation of 18 F-FAPI-74 and a proof of mechanism for 68 Ga-FAPI-74 labeled at ambient temperature. Methods: In 10 patients with lung cancer, PET scans were acquired at 10 min, 1 h, and 3 h after administration of 259 ± 26 MBq of 18 F-FAPI-74. Physiologic biodistribution and tumor uptake were semiquantitatively evaluated on the basis of SUV at each time point. Absorbed doses were evaluated using OLINDA/EXM, version 1.1, and QDOSE dosimetry software with the dose calculator IDAC-Dose, version 2.1. Identical methods were used to evaluate one examination after injection of 263 MBq of 68 Ga-FAPI-74. Results: The highest contrast was achieved in primary tumors, lymph nodes, and distant metastases at 1 h after injection, with an SUV max of more than 10. The effective dose per a 100-MBq administered activity of 18 F-FAPI-74 was 1.4 ± 0.2 mSv, and for 68 Ga-FAPI-74 it was 1.6 mSv. Thus, the radiation burden of a diagnostic 18 F-FAPI-74 PET scan is even lower than that of PET scans with 18 F-FDG and other 18 F tracers; 68 Ga-FAPI-74 is comparable to other 68 Ga ligands. FAPI PET/CT supported target volume definition for guiding radiotherapy. Conclusion: The high contrast and low radiation burden of FAPI-74 PET/CT favor multiple clinical applications. Centralized large-scale production of 18 F-FAPI-74 or decentralized cold-kit labeling of 68 Ga-FAPI-74 allows flexible routine use.
(© 2021 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze: MEDLINE
Externí odkaz: